Shankar Siva, MBBS, PhD, FRANZCR, discussed when to consider cytoreductive SABR in patients with metastatic kidney cancer responding to systemic therapy.

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists perform brachytherapy, and one setting where he considers it the better option.

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence and the data that shaped his approach.

Tyler J. Wilhite, MD, discussed coordinating with rheumatology, orthopedic surgery, and primary care when treating patients with osteoarthritis with low-dose radiation therapy.

Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.

Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.

At The Liver Meeting 2026, Ryosuke Tateishi, MD, PhD, discussed what the US and Japan can learn from each other to prevent liver cancer.

At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.